Cyclic pantetheine derivatives and uses thereof
AssigneeVectivBio Comet AG
InventorsArthur George TAVERAS, Enej KUSCER, Angelina Roberta SEKIRNIK, Dharini SHAH, Mercedes VALLS SERON
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds of Formula (P) or (II′-0): (Formulae (I′), (II′-0)), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.
Claims337
A compound of Formula (I′) or (II′-0):
- or a pharmaceutically acceptable salt or solvate thereof, wherein:
- each T is independently
- each Rt is independently R1, R1a, R1b or R1c;
- or
- two Rt, together with the one or more intervening atoms they are attached to, form a C3-C12 cycloalkyl or C3-C12 heterocycloalkyl, wherein C3-C12 cycloalkyl or C3-C12 heterocycloalkyl is optionally substituted with one or more R1a;
- t is an integer ranging from 0 to 5;
- R1 is H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkenyl, —C(═O)R1b, —C(═O)R1z, —C(═O)—(CH═CH)n—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)CH(R1a)—[C(═O)CH(R1a)]p—[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]p—[CH2]q—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH(OR1c)—CH2]r[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]r—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)OR1c, —C(═O)N(R1c)2, —C(═O)—CH═CH—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)OR1c, —C(═O)—CH2CH2—C(═O)OR1c, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)R1z, —C(═O)—CH2CH2—C(═O)R1z, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)R1z, —SR1d,
- wherein the C1-C20 alkyl, C2-C20 alkenyl or C2-C20 alkynyl is optionally substituted with one or more R1a, and wherein one or more methylene moieties in the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl are optionally replaced by one or more carbonyl moieties;
- each R1a is independently H, oxo, halogen, C1-C20 alkyl, C2-C20 alkenyl, —OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, —N(R1c)2, —N(R1c)C(═O)R1b, —N(R1c)C(═O)R1z, —N(R1c)C(═O)OR1c, —OC(═O)R1b, —OC(═O)R1z, —OC(═O)OR1c, —OSi(R1g)3, —SC(═O)R1b, —SC(═O)R1z, —SC(═O)OR1c, —SC(═O)N(R1c)2, —C(═O)R1b, —C(═O)R1z, —SR1d, or R1g, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1e;
- each R1b is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —(CH2)q—C(═O)OR1c, —CH2—C(═O)—(CH2)q—C(═O)OR1c, —CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, C(═O)OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1e;
- each R1c is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1c;
- or two R1c together with the one or more intervening atoms to which they are connected, form C3-C12 cycloalkyl or C3-C12 heterocycloalkyl, wherein the C3-C12 cycloalkyl or C3-C12 heterocycloalkyl is optionally substituted with one or more R1e;
- each R1d is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C10 cycloalkyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1e;
- each R1e is independently H, halogen, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, —N(R1g)2, —N(R1g)C(═O)R1f, —N(R1g)C(═O)R1z, —N(R1g)C(═O)OR1g, —OC(═O)R1f, —OC(═O)R1z, —OC(═O)OR1g, —OSi(R1g)3, —SR1g, —N+(R1g)3, —SC(═O)R1f, —SC(═O)R1z, —SC(═O)OR1g, —SC(═O)N(R1g)2, —C(═O)R1f, —C(═O)R1z, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1z;
- each R1f is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —OSi(R1g)3, —CH2C(═O)OR1g, —CH═CH—C(═O)OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, or R1g, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1g;
- each R1g is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C2 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C2 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1z;
- each R1z is independently
- each n is independently an integer ranging from 0 to 20;
- each p is independently an integer ranging from 0 to 20;
- each q is independently an integer ranging from 0 to 20;
- each r is independently an integer ranging from 0 to 20;
- each X is independently —OR1c, —SR1c, —N(R1c)2,
- or R1z;
- and
- Y is a bond or C1-C20 alkyl optionally substituted with one or more R1e.
A compound of Formula (I′) or (II′):
- or a pharmaceutically acceptable salt or solvate thereof, wherein:
- each T is independently
- each Rt is independently R1, R1a, or R1b;
- or
- two Rt, together with the one or more intervening atoms they are attached to, form a C3-C12 cycloalkyl or C3-C12 heterocycloalkyl, wherein C3-C12 cycloalkyl or C3-C12 heterocycloalkyl is optionally substituted with one or more R1a;
- t is an integer ranging from 0 to 5;
- R1 is H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —C(═O)R1b, —C(═O)R1z, —C(═O)—(CH═CH)n—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)CH(R1a)—[C(═O)CH(R1a)]p—[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]p—[CH2]q—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH(OR1c)—CH2]r[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]r—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)OR1c, —C(═O)N(R1c)2, —C(═O)—CH═CH—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)OR1c, —C(═O)—CH2CH2—C(═O)OR1c, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)R1z, —C(═O)—CH2CH2—C(═O)R1z, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)R1z, —SR1d,
- wherein the C1-C20 alkyl, C2-C20 alkenyl or C2-C20 alkynyl is optionally substituted with one or more R1a, and wherein one or more methylene moieties in the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl are optionally replaced by one or more carbonyl moieties;
- each R1a is independently H, oxo, halogen, C1-C20 alkyl, C2-C20 alkenyl, —OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, —N(R1c)2, —N(R1c)C(═O)R1b, —N(R1c)C(═O)R1z, —N(R1c)C(═O)OR1c, —OC(═O)R1b, —OC(═O)R1z, —OC(═O)OR1c, —SC(═O)R1b, —SC(═O)R1z, —SC(═O)OR1c, —SC(═O)N(R1c)2, —C(═O)R1b, —C(═O)R1z, —SR1d, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1d;
- each R1b is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —(CH2)q—C(═O)OR1c, —CH2—C(═O)—(CH2)q—C(═O)OR1c, —CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, —CH—H—C(═O)OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1e;
- each R1c is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1e;
- each R1d is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C10 cycloalkyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1e;
- each R1e is independently H, halogen, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, —N(R1g)2, —N(R1g)C(═O)R1f, —N(R1g)C(═O)R1z, —N(R1g)C(═O)OR1g, —OC(═O)R1f, —OC(═O)R1z, —OC(═O)OR1g, —SR1g, —N+(R1g)3, —SC(═O)R1f, —SC(═O)R1z, —SC(═O)OR1g, —SC(═O)N(R1g)2, —C(═O)R1f, —C(═O)R1z, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1z;
- each R1f is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —CH2C(═O)OR1g, —CH═CH—C(═O)OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1z;
- each R1g is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C2 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1z;
- each R1z is independently
- each n is independently an integer ranging from 0 to 20;
- each p is independently an integer ranging from 0 to 20;
- each q is independently an integer ranging from 0 to 20;
- each r is independently an integer ranging from 0 to 20;
- and
- each X is independently —OR1c, —SR1c, —N(R1c)2,
- or R1z.
A compound of Formula (I), (II), (III), (IV), (V), or (VI):
- or a pharmaceutically acceptable salt or solvate thereof, wherein:
- R1 is H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —C(═O)R1b, —C(═O)R1z, —C(═O)—(CH═CH)n—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]p—[CH2]q—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH(OR1c)—CH2]r[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]r—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)OR1c, —C(═O)N(R1c)2, —C(═O)—CH═CH—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)OR1c, —C(═O)—CH2CH2—C(═O)OR1c, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)R1z, —C(═O)—CH2CH2—C(═O)R1z, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)R1z, —SR1d,
- wherein the C1-C20 alkyl, C2-C20 alkenyl or C2-C20 alkynyl is optionally substituted with one or more R1a, and wherein one or more methylene moieties in the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl are optionally replaced by one or more carbonyl moieties;
- each R1a is independently H, oxo, halogen, C1-C20 alkyl, C2-C20 alkenyl, —OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, —N(R1c)2, —N(R1c)C(═O)R1b, —N(R1c)C(═O)R1z, —N(R1c)C(═O)OR1c, —OC(═O)R1b, —OC(═O)R1z, —OC(═O)OR1c, —SC(═O)R1b, —SC(═O)R1z, —SC(═O)OR1c, —SC(═O)N(R1c)2, —C(═O)R1b, —C(═O)R1z, —SR1d, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1c;
- each R1b is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —(CH2)q—C(═O)OR1c, —CH2—C(═O)—(CH2)q—C(═O)OR1c, —CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, —CH═CH—C(═O)OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1e;
- each R1c is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1e;
- each R1d is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C10 cycloalkyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12, heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1e;
- each R1e is independently H, halogen, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, —N(R1g)2, —N(R1g)C(═O)R1f, —N(R1g)C(═O)R1z, —N(R1g)C(═O)OR1g, —OC(═O)R1c, —OC(═O)R1z, —OC(═O)OR1g, —SR1g, —N+(R1g)3, —SC(═O)R1f, —SC(═O)R1z, —SC(═O)OR1g, —SC(═O)N(R1g)2, —C(═O)R1f, —C(═O)R1z, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1z;
- each R1f is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —CH2C(═O)OR1g, —CH═CH—C(═O)OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, or R1g, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1z;
- each R1g is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1f,
- each R1f is independently
- each n is independently an integer ranging from 0 to 20;
- each p is independently an integer ranging from 0 to 20;
- each q is independently an integer ranging from 0 to 20;
- each r is independently an integer ranging from 0 to 20;
- and
- each X is independently —OR1c, —SR1c, —N(R1c)2,
The compound of any one of the preceding claims, wherein R1 is C1-20 alkyl.
The compound of any one of the preceding claims, wherein R1 is —C(═O)R1b.
The compound of any one of the preceding claims, wherein R1 is —C(═O)R1z.
The compound of any one of the preceding claims, wherein R1 is
The compound any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is —C(═O)—(CH═CH)n—R1a.
The compound of an one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is [C(═O)CH2]p—[CH2]q—R1a.
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is —C(═O)CH(R1a)—[C(═O)CH(R1a)]p—[CH2]q—R1a.
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims,
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is —C(═O)CH2—[CH(OR1c)—CH2]p—[CH2]q—R1a.
The compound of any one of the preceding claims, wherein R1 is —C(═O)CH2—[C(═O)CH2]p—[CH(OR1c)—CH2]r—[CH2]q—R1a.
The compound of any one of the preceding claims, wherein R1 is —C(═O)CH2—[CH(OR1c)—CH2]r[C(═O)CH2]p—[CH2]q—R1a.
The compound of any one of the preceding claims, wherein R1 is —C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1 is C(═O)N(R1c)2.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH═CH—C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—[CH2]q—C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1 is —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—[CH2]q—C(═O)R1z.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—C(═O)R1z.
The compound of any one of the preceding claims, wherein R1 is —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)R1z.
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1 is
The compound of any one of the preceding claims, wherein R1a is H.
The compound of any one of the preceding claims, wherein R1a is C1-C20 alkyl.
The compound of any one of the preceding claims, wherein R1a is C2-C20 alkenyl.
The compound of any one of the preceding claims, wherein R1a is —OR1c.
The compound of any one of the preceding claims, wherein R1a is —C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1a is —C(═O)R1b.
The compound of any one of the preceding claims, wherein R1a is —C(═O)R1z.
The compound of any one of the preceding claims, wherein R1a is R1z.
The compound of any one of the preceding claims, wherein R1b is C1-C20 alkyl.
The compound of any one of the preceding claims, wherein R1b is C2-C20 alkenyl.
The compound of any one of the preceding claims, wherein R1b is —(CH2)q—C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1b is —CH2—C(═O)—(CH2)q—C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1b is —CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1b is —CH—H—C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1b is R1z.
The compound of any one of the preceding claims, wherein R1c is H.
The compound of any one of the preceding claims, wherein R1c is C1-20 alkyl.
The compound of any one of the preceding claims, wherein R1c is C2-20 alkenyl.
The compound of any one of the preceding claims, wherein R1c is —(C1-C20 alkyl)-(C3-C12 cycloalkyl).
The compound of any one of the preceding claims, wherein R1c is —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl).
The compound of any one of the preceding claims, wherein R1c is —(C1-C20 alkyl)-(C3-C12 aryl).
The compound of any one of the preceding claims, wherein R1c is —(C1-C20 alkyl)-(C3-C12 heteroaryl).
The compound of any one of the preceding claims, wherein R1d is H.
The compound of any one of the preceding claims, wherein R1d is C1-C20 alkyl.
The compound of any one of the preceding claims, wherein R1d is C2-C20 alkenyl.
The compound of any one of the preceding claims, wherein R1d is C3-C12 cycloalkyl.
The compound of any one of the preceding claims, wherein R1d is C3-C12 heterocycloalkyl.
The compound of any one of the preceding claims, wherein R1d is C3-C12 aryl.
The compound of any one of the preceding claims, wherein R1d is C3-C12 heteroaryl.
The compound of any one of the preceding claims, wherein R1d is —(C1-C20 alkyl)-(C3-C12 cycloalkyl).
The compound of any one of the preceding claims, wherein R1d is —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl).
The compound of any one of the preceding claims, wherein R1d is —(C1-C20 alkyl)-(C3-C12 aryl).
The compound of any one of the preceding claims, wherein R1d is —(C1-C20 alkyl)-(C3-C12 heteroaryl).
The compound of any one of the preceding claims, wherein R1e is H.
The compound of any one of the preceding claims, wherein R1e is C1-C20 alkyl.
The compound of any one of the preceding claims, wherein R1e is C2-C10 alkenyl.
The compound of any one of the preceding claims, wherein R1e is —OR1g.
The compound of any one of the preceding claims, wherein R1e is —C(═O)OR1g.
The compound of any one of the preceding claims, wherein R1e is —C(═O)OR1f.
The compound of any one of the preceding claims, wherein R1e is —C(═O)R1z.
The compound of any one of the preceding claims, wherein R1e is —N(R1g)C(═O)R1z.
The compound of any one of the preceding claims, wherein R1e is —OC(═O)R1z.
The compound of any one of the preceding claims, wherein R1e is —N+(R1g)3.
The compound of any one of the preceding claims, wherein R1e is R1z.
The compound of any one of the preceding claims, wherein R1f is H.
The compound of any one of the preceding claims, wherein R1f is C1-C20 alkyl.
The compound of any one of the preceding claims, wherein R1f is C2-C20 alkenyl.
The compound of any one of the preceding claims, wherein R1f is —CH2C(═O)OR1g.
The compound of any one of the preceding claims, wherein R1f is —CH═CH—C(═O)OR1g.
The compound of any one of the preceding claims, wherein R1f is —C(═O)OR1g.
The compound of any one of the preceding claims, wherein R1f is R1z.
The compound of any one of the preceding claims, wherein R1z is
The compound of any one of the preceding claims, wherein R1z is
The compound of any one of the preceding claims, wherein R1z is
The compound of any one of the preceding claims, wherein n is 0 to 4.
The compound of any one of the preceding claims, wherein n is 0.
The compound of any one of the preceding claims, wherein n is 1.
The compound of any one of the preceding claims, wherein n is 2.
The compound of any one of the preceding claims, wherein p is 0 to 4.
The compound of any one of the preceding claims, wherein p is 0.
The compound of any one of the preceding claims, wherein p is 1.
The compound of any one of the preceding claims, wherein p is 2.
The compound of any one of the preceding claims, wherein q is 0 to 4.
The compound of any one of the preceding claims, wherein q is 0.
The compound of any one of the preceding claims, wherein q is 1.
The compound of any one of the preceding claims, wherein q is 2.
The compound of any one of the preceding claims, wherein r is 0 to 4.
The compound of any one of the preceding claims, wherein r is 0.
The compound of any one of the preceding claims, wherein r is 1.
The compound of any one of the preceding claims, wherein r is 2.
The compound of any one of the preceding claims, wherein X is —OR1c.
The compound of any one of the preceding claims, wherein X is —SR1c.
The compound of any one of the preceding claims, wherein X is —N(R1c)2.
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is R1z.
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein X is
The compound of any one of the preceding claims, wherein at least one T is
The compound of any one of the preceding claims, wherein at least one T is
The compound of any one of the preceding claims, wherein at least one T is
The compound of any one of the preceding claims, wherein at least one T is
The compound of any one of the preceding claims, wherein at least one T is
The compound of any one of the preceding claims, wherein at least one T is
The compound of any one of the preceding claims, wherein at least one T is
The compound of any one of the preceding claims, wherein Rt is R1.
The compound of any one of the preceding claims, wherein Rt is R1a.
The compound of any one of the preceding claims, wherein Rt is R1b.
The compound of any one of the preceding claims, wherein two Rt form a C3-C12 cycloalkyl.
The compound of any one of the preceding claims, wherein two Rt form a C1-C12 heterocycloalkyl.
The compound of any one of the preceding claims, wherein two Rt form a C3-C12 cycloalkyl optionally substituted with one or more R1a.
The compound of any one of the preceding claims, wherein two Rt form a C3-C12 heterocycloalkyl optionally substituted with one or more R1a.
The compound of any one of the preceding claims, wherein t is 1.
The compound of any one of the preceding claims, wherein t is 2.
The compound of any one of the preceding claims, being of Formula (I′-1) or (I′-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, wherein each T is independently
The compound of any one of the preceding claims, wherein each T is independently
The compound of any one of the preceding claims, wherein each T is independently
The compound of any one of the preceding claims, wherein each T is independently
The compound of any one of the preceding claims, wherein each T is independently
The compound of any one of the preceding claims, wherein each T is independently
The compound of any one of the preceding claims, wherein each T is independently
The compound of any one of the preceding claims, wherein R1 is —C(═O)—R1a, —C(═O)—CH2—R1a, —C(═O)—CH2CH2—R1a or —C(═O)—CH═CH—R1a, wherein R1a is C1-C20 alkyl, —C(═O)R1b, or —C(═O)OR1c, wherein the C1-C20 alkyl is optionally substituted with one or more Rio.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—R1a, wherein —R1a is C1-C20 alkyl.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH3.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—R1a, wherein R1a is C1-C20 alkyl optionally substituted with one or more R1e, wherein R1e is —OH.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—R1a, wherein R1a is ethyl substituted one —OH.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—CH(OH)—CH3.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—R1a, wherein R1a is —C(═O)R1b.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—C(═O)—R1b, wherein R1b is C1-C20 alkyl.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—C(═O)—CH3.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—R1a, wherein R1a is C1-C20 alkyl or —C(═O)OR1c
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—C(═O)OR1c, wherein R1c is H or C1-C20 alkyl.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—C(═O)OH.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—C(═O)OCH3.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH═CH—R1a, wherein —R1a is C1-C20 alkyl or —C(═O)OR1c.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH—H—R1a, wherein —R1a is C1-C20 alkyl.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH—H—CH3.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH═CH—C(═O)OR1c, wherein R1c is H or C1-C20 alkyl.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH—H—C(═O)OH.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH—H—C(═O)OCH3.
The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH3, —C(═O)—CH2—CH(OH)—CH3, —C(═O)—CH2—C(═O)—CH3, —C(═O)—CH2CH2—C(═O)OH, —C(═O)—CH2CH2—C(═O)OCH3, —C(═O)—CH═CH—CH3, —C(═O)—CH═CH—C(═O)OH, or —C(═O)—CH═CH—C(═O)OCH3.
The compound of any one of the preceding claims, wherein each T is independently
- and R1 is —C(═O)—R1a, —C(═O)—CH2—R1a, —C(═O)—CH2CH2—R1a or —C(═O)—CH═CH—R1a, wherein R1a is C1-C20 alkyl, —C(═O)R1b, or —C(═O)OR1c, wherein the C1-C20 alkyl is optionally substituted with one or more R1e.
The compound of any one of the preceding claims, wherein each T is independently
- and R1 is —C(═O)—CH3, —C(═O)—CH2—CH(OH)—CH3, —C(═O)—CH2—C(═O)—CH3, —C(═O)—CH2CH2—C(═O)OH, —C(═O)—CH2CH2—C(═O)OCH3, —C(═O)—CH═CH—CH3, —C(═O)—CH═CH—C(═O)OH, or —C(═O)—CH═CH—C(═O)OCH3.
The compound of any one of the preceding claims, being of Formula (Ia′):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ia′-1) or (Ia′-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ib′):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ib′-1) or (Ib′-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (II′-1) or (II′-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IIa′):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IIa′-1) or (IIa′-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IIb′):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IIb′-1) or (IIb′-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (I-1) or (I-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Iaa), (Iab), (Iac), or (Iad):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Iaa-1), (Iaa-2), (Iab-1), (Iab-2), (Iac-1), (Iac-2), (Iad-1), or (Iad-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Iae), (Iaf), (Iag), or (Iah):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Iae-1), (Iae-2), (Iaf-1), (Iaf-2), (Iag-1), (Iag-2), (Iah-1), or (Iah-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Iai), (Iaj), (Iak), (Ial), (Iam), or (Ian):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Iai-1), (Iai-2), (Iaj-1), (Iaj-2), (Iak-1), (Iak-2), (Ial-1), (Ial-2), (Iam-1), (Iam-2), (Ian-1), or (Ian-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Iba), (Ibb), (Ibc), or (Ibd):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Iba-1), (Iba-2), (Ibb-1), (Ibb-2), (Ibc-1), (Ibc-2), or (Ibd-1), or (Ibd-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ibe), or (Ibf):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ibe-1), (Ibe-2), (Ibf-1), or (Ibf-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ibg), (Ibh), (Ibi), or (Ibj):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ibg-1), (Ibg-2), (Ibh-1), (Ibh-2), (Ibi-1), (Ibi-2), (Ibi-1), or (Ibi-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ibk), (Ibl), (Ibm), or (Ibn):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ibk-1), (Ibk-2), (Ibl-1), (Ibl-2), (Ibm-1), (Ibm-2), (Ibn-1), or (Ibn-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ibo), (Ibp), (Ibq), or (Ibr):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (Ibo-1), (Ibo-2), (Ibp-1), (Ibp-2), (Ibq-1), (Ibq-2), (Ibr-1), or (Ibr-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (II-1) or (II-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IIaa), (IIab), (IIac), or (IIad):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IIaa-1), (IIaa-2), (IIab-1), (IIab-2), (IIac-1), (IIac-2), (IIad-1), or (IIad-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IIae), (IIaf), (IIag), or (IIah):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IIae-1), (IIae-2), (IIaf-1), (IIaf-2), (IIag-1), (IIag-2), (IIah-1), or (IIah-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IIai), (IIaj), (IIak), (IIal), (IIam), or (IIan):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IIai-1), (IIai-2), (IIaj-1), (IIaj-2), (IIak-1), (IIak-2), (IIal-1), (IIal-2), (IIam-1), (IIam-2), (IIan-1), or (IIan-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (III-1) or (III-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (IV-1) or (IV-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (V-1) or (V-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being of Formula (VI-1) or (VI-2):
- or a pharmaceutically acceptable salt or solvate thereof.
The compound of any one of the preceding claims, being selected from the compounds described in Table 1 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 1-446 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 447-516 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 517-527 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 528-555 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 556-581 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 582-607 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 608-699 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 700-747 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 748-794 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 795-818 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 819-844 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 849-932 and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 1, 5, 21, 36, 39, 42, 61, 447, 448, and 485, and pharmaceutically acceptable salts thereof.
The compound of any one of the preceding claims, being selected from Compound Nos. 1, 5, 21, 36, 39, 42, 61, 447, 448, and 485.
A compound being an isotopic derivative of the compound of any one of the preceding claims.
A compound being an intermediate obtained by a method for preparing the compound of any one of the preceding claims.
A pharmaceutical composition comprising the compound of any one of the preceding claims or a pharmaceutically acceptable salt thereof.
A method of activating or enhancing acetyl-CoA synthesis in a subject comprising administering to the subject a therapeutically effective amount a compound of any one of the preceding claims.
A method of increasing acetyl-CoA concentrations in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating a subject having a disease comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing a disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of decreasing degradation of CoA in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of increasing the half-life of CoA in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of prolonging the availability of CoA in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of delivering an acyl moiety into the mitochondrial matrix of a mitochondrion of a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of decreasing the concentration of reactive oxygen species (ROS) in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of decreasing the concentration of an at least one acyl-CoA species in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of increasing the fatty acid metabolism in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of increasing the amino acid metabolism in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of increasing mitochondrial respiration in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of increasing ATP concentration in a subject comprising administering to the subject therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating a subjecting having a cancer comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing a cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of reducing the size of a tumor comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of inducing tumor cell apoptosis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of inducing cell cycle arrest in a tumor cell in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of inducing differentiation of a cell in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of inducing senescence in a cell in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of enhancing an immune response against cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of inhibiting angiogenesis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of enhancing the apoptotic effect of an anti-cancer agent comprising administering to a subject a combination of a therapeutically effective amount of the anti-cancer agent and a therapeutically effective amount of a compound of any one of the preceding claims.
A method of increasing the post-translational modification of proteins in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of increasing acetylation of proteins in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of increasing acetylation of histones in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of increasing acetylation of tubulin in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating a subject having a neurodegenerative disease comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing a neurodegenerative disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating a subject having an ataxia disease comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing an ataxia in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating nonalcoholic steatohepatitis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing nonalcoholic steatohepatitis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating nonalcoholic fatty liver disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing nonalcoholic fatty liver disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing an inappropriate shift to fatty acid biosynthesis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating an inflammatory disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing an inflammatory disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of reducing inflammation in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of reducing fibrosis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of stimulating the activity of Regulatory T cells in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating Crohn's disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing Crohn's disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating colitis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing colitis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating chronic intestinal inflammation in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing chronic intestinal inflammation in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating HIV in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating HIV in a subject comprising administering to the subject a combination of a therapeutically effective amount of a compound of any one of the preceding claims and a therapeutically effective amount of an immune modulator compound.
A method of treating HIV in a subject comprising administering to the subject a combination of a therapeutically effective amount of a compound of any one of the preceding claims and a therapeutically effective amount of an anti-HIV agent.
A method of reactivating latent HIV in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of reactivating latent HIV without inducing global T cell activation in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating Acute Coronary Syndrome in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of reducing damage to cardiac cells in a subject having acute coronary syndrome comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of reducing damage imparted by ischemia, inflammation, fibrotic remodeling or any combination thereof in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing reinfarction in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing ischemic stroke in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of increasing the survival of cardiac cells in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating major depressive disorder in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing major depressive disorder in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of reversing acetylation patterns induced by major depressive disorder in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of augmenting the therapeutic effect of an anti-depressant compound in a subject comprising administering to the subject a combination of a therapeutically effective amount of the anti-depressant compound and a therapeutically effective amount of a compound of any one of the preceding claims.
A method of improving mitochondrial health in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of reducing neuroinflammation in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of improving neuronal function comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of improving neuronal survival comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of inhibiting microglial-mediated neuroinflammation comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating a subject having Huntington's disease comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of preventing Huntington's disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of re-establishing CoA homeostasis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
The compound of any one of the preceding claims for use in increasing acetyl-CoA concentrations in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A use of the compound of any one of the preceding claims for the manufacture of a medicament for increasing acetyl-CoA concentrations in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
The compound of any one of the preceding claims for use in treating a disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A use of the compound of any one of the preceding claims for the manufacture of a medicament for treating a disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
The compound of any one of the preceding claims for use in preventing a disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A use of the compound of any one of the preceding claims for the manufacture of a medicament for preventing a disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
The compound of any one of the preceding claims for use in treating a cancer in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A use of the compound of any one of the preceding claims for the manufacture of a medicament for treating a cancer in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
The compound of any one of the preceding claims for use in preventing a cancer in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A use of the compound of any one of the preceding claims for the manufacture of a medicament for preventing a cancer in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
The compound of any one of the preceding claims for use in treating an inflammatory disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A use of the compound of any one of the preceding claims for the manufacture of a medicament for treating an inflammatory disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
The compound of any one of the preceding claims for use in preventing an inflammatory disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A use of the compound of any one of the preceding claims for the manufacture of a medicament for preventing an inflammatory disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
The compound of any one of the preceding claims for use in treating a neurodegenerative disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A use of the compound of any one of the preceding claims for the manufacture of a medicament for treating a neurodegenerative disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
The compound of any one of the preceding claims for use in preventing a neurodegenerative disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A use of the compound of any one of the preceding claims for the manufacture of a medicament for preventing a neurodegenerative disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A method of treating a subject having multiple sclerosis comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating a subject having epilepsy comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of treating a subject having schizophrenia comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A method of restoring acetylation of proteins from a hypo-acetylated state comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A compound of any one of the preceding claims for use in treating an acute kidney injury in a subject, wherein the acetyl-CoA precursor is for administration to the subject in at least one therapeutically effective amount.
A compound of any one of the preceding claims for the manufacture of a medicament for treating an acute kidney injury in a subject, wherein the acetyl-CoA precursor is for administration to the subject in at least one therapeutically effective amount.
A compound of any one of the preceding claims for use in preventing an acute kidney injury in a subject, wherein the acetyl-CoA precursor is for administration to the subject in at least one therapeutically effective amount.
A compound of any one of the preceding claims for the manufacture of a medicament for preventing an acute kidney injury in a subject, wherein the acetyl-CoA precursor is for administration to the subject in at least one therapeutically effective amount.
A method of treating a subject having a mitochondrial disease comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.
A compound of any one of the preceding claims for the manufacture of a medicament for treating a mitochondrial disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
A compound of any one of the preceding claims for use in treating a mitochondrial disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
Dependencies are inferred from the claim text.